TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 03/20/23

2023-03-20 06:45:56 ET TAK-279, an experimental tyrosine kinase 2 (TYK2) inhibitor developed by Takeda Pharmaceutical ( NYSE: TAK ), reached the primary and secondary endpoints in a mid-stage trial for patients with plaque psoriasis, the company announced. The Phase 2b study...

Results for TAK-279 (Formerly NDI-034858) Show a Significantly Greater Proportion of Patients Achieved Psoriasis Area and Severity Index (PASI) 75 at Doses ≥5mg at 12 Weeks 1 At the Highest Dose of TAK-279, 46% of Patients Achieved PASI 90 and 33% Achieved PASI 100 ...

2023-03-16 17:50:07 ET Summary BioCryst Pharmaceuticals is a biotech company that focuses on developing treatments for rare diseases. Its main product, Orladeyo, is an oral medication approved by the FDA to treat hereditary angioedema. BioCryst's full-year 2022 revenue for Orladey...

2023-03-16 14:15:32 ET Big pharma held steady on Thursday after the Centers for Medicare & Medicaid Services (CMS) issued initial guidance on the Medicare drug price negotiation program, which will go into effect in 2026. The program comes under President Biden's Inflation Reduc...

2023-03-16 11:40:03 ET Bank of America upgraded Takeda Pharmaceutical ( NYSE: TAK ) to Buy from Neutral on Thursday, citing growth prospects and deleveraging efforts in a company that, according to the firm, has traded as “a value stock for a protracted time.” ...

2023-03-16 07:35:38 ET Summary Takeda's late-stage pipeline is impressive with many candidates boasting very strong fundamentals. Technically though, shares are now coming up against significant overhead resistance. Dividend growth rates remain sluggish. Yield chasers need to ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its announcement on January 23, 2023 and following the completion of customary closing ...

2023-03-09 09:05:52 ET Exelixis ( NASDAQ: EXEL ) shares ticked higher in the pre-market trading Thursday after Wells Fargo launched its coverage on the cancer drugmaker with an Overweight recommendation and a $23 per share target citing the sales potential of its lead rev...

Summary My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Meta and Tesla helped fuel another market beat in 2023 for me in February even disregarding depositing my 2022 IRA co...

FBI Director Christopher Wray said that the agency believes that the novel coronavirus which causes COVID-19 likely originated from a lab leak in Wuhan, China. "The FBI has for quite some time now assessed that the origins of the pandemic are most likely a potential lab incident in Wuhan," Wr...